Share

Bypass and Beyond: Redefining Roles and Mechanisms of Obesity Treatment at ENDO 2025

Endocrine News talks with the chair and presenters of “Bariatric Surgery and Emerging Medications: Redefining Roles and Mechanisms,”an ENDO 2025 session that analyzes a variety of factors that are impacted by bariatric surgery including postsurgical hypoglycemia, surgery versus pharmacological solutions, as well as a number of molecular mechanisms of the surgery itself. With so many...
Share

Pharma Fridays – June 6, 2025

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist On June 2, Regeneron Pharmaceuticals, Inc., announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited (“Hansoh”) to acquire exclusive clinical development and commercial rights outside of the...
Share

Endocrine Society Endorses Treat and Reduce Obesity Act

The Endocrine Society today endorsed the introduction of the bipartisan Treat and Reduce Obesity Act (TROA) in the Senate.  The legislation will ensure that Medicare and Medicaid beneficiaries have access to effective anti-obesity medications. Medicare coverage of anti-obesity medications is currently prohibited under law.  Access to these medications would benefit millions of Americans. More than...
Share

Saliva Test One Step Closer to Replacing Blood Work for Adrenal Disorder Diagnosis

Salivary cortisol and cortisone can be valuable tools in diagnosing adrenal insufficiency (AI), offering non-invasive options for screening and potentially avoiding the need for ACTH stimulation tests in some cases, states a recent study in The Journal of Clinical Endocrinology and Metabolism. Adrenal insufficiency (AI), such as in cases of Addison’s disease and Congenital Adrenal Hyperplasia,...
Share

Easy Targets: How Endocrine-Disrupting Chemicals Affect Reproductive Endocrinology

Veiga-Lopez_Almudena-cropped-600x676 Endocrine-disrupting chemicals have been implicated in a wide range of poor health outcomes, including infertility and obesity. Endocrine News speaks to Almudena Veiga-Lopez, DVM, PhD, the chair of an upcoming ENDO 2025 symposium on these chemicals’ effects on reproductive organs, which are particularly vulnerable to EDCs. Endocrine-disrupting chemicals are everywhere, and there is seemingly no...
Share

Endocrine Society Makes Strides Over Past 12 Months

John_Newell-Price As I come to the end of my term at ENDO 2025 next month in San Francisco, Calif., I can look back with great pride at what the Endocrine Society has accomplished over the past 12 months. My experience as your president also has reaffirmed my belief that belonging to a strong community is crucial...
Share

Hidden Steroids in Arthritis Supplements Raise Serious Adrenal Concerns

JES cover Before you reach for that arthritis supplement, take note: Over-the-counter supplements could contain surreptitious glucocorticoids, notes a new case series study published in The Journal of The Endocrine Society. The study describes 12 patients who developed Cushing syndrome (CS) and/or adrenal insufficiency (AI) after consuming commonly used supplements such as Artri King, Ardosons, and Ajo...
Share

Sriram Gubbi of NIDDK Wins Endocrine Society’s 2025 Endocrine Images Art Competition 

SGubbi headshot for ENDO 2025 “Cosmic Bubble” image features cells from a thyroid cancer subtype  Sriram Gubbi, MD, won the Endocrine Society’s 2025 Endocrine Images Art Competition with his microphotograph of follicular thyroid carcinoma cells titled “The Cosmic Bubble”.   The art competition celebrates the beauty of endocrine science as seen through the lens of a microscope. More than 30 entries...
Show More